Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
NCT03014622 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 303
Last updated 2022-07-21
Summary
This is a safety and efficacy study of DaxibotulinumtoxinA for Injection to treat moderate to severe frown lines.
Conditions
- Glabellar Frown Lines
Interventions
- BIOLOGICAL
-
Botulinum Toxins, Type A
Intramuscular injection
- BIOLOGICAL
-
Placebos
Intramuscular injection
Sponsors & Collaborators
-
Revance Therapeutics, Inc.
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-12-08
- Primary Completion
- 2017-11-14
- Completion
- 2017-11-14
Countries
- United States
Study Locations
More Related Trials
-
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines
NCT04259086 ·Status: COMPLETED ·Phase: PHASE2
-
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I
NCT02677298 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101)
NCT06585696 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines
NCT06308198 ·Status: COMPLETED ·Phase: PHASE3
-
To Evaluate the Safety and Efficacy of Botulax® Are Not Inferior to Those of Botox® in the Treatment of Glabellar Lines
NCT01791920 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
NCT03911102 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines
NCT06212960 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
NCT00968942 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines
NCT04143815 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of PurTox® Botulinum Toxin Type A to Treat Frown Lines Between the Eyebrows
NCT00752297 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines
NCT04622254 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Moderate to Severe Glabellar Lines
NCT04249583 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
NCT05217355 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
NCT03736928 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines
NCT03960957 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
NCT00968825 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects
NCT03970876 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Effectiveness of Sculptra Aesthetic for Correction of Cheek Wrinkles
NCT04124692 ·Status: COMPLETED ·Phase: NA
-
Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
NCT05320393 ·Status: COMPLETED ·Phase: PHASE2
-
A Long-Term Safety Study of Repeat Treatment With PurTox® for Frown Lines Between the Eyebrows
NCT00752258 ·Status: COMPLETED ·Phase: PHASE3
-
DaxibotulinimtoxinA for Treatment of Platysmal Neck Bands
NCT06225492 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial
NCT05804656 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines
NCT07013279 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines
NCT05059587 ·Status: COMPLETED ·Phase: PHASE3
-
Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines
NCT06151561 ·Status: COMPLETED ·Phase: PHASE1